Overview

Safety and Tolerability of Lixisenatide in Combination With Oral Anti-Diabetic Treatment in Patients With Type 2 Diabetes

Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
Primary Objective: The primary objective of this study is to assess the overall safety of lixisenatide once daily treatment in combination with background oral anti-diabetic treatment over 52 weeks in patients with type 2 diabetes in Japan. Secondary Objective: To assess the effects of lixisenatide in combination with background oral antidiabetic drug (OAD) on: - HbA1c; - Fasting plasma glucose; - Body weight.
Phase:
Phase 3
Details
Lead Sponsor:
Sanofi
Treatments:
Biguanides
Hypoglycemic Agents
Lixisenatide